Mizuho Securities USA LLC Decreases Holdings in Humana Inc. (NYSE:HUM)

Key Points

• Mizuho Securities USA LLC has reduced its stake in Humana Inc. by 15.4% during the first quarter, resulting in a holding of 9,660 shares valued at approximately $2.56 million.
• Multiple hedge funds, including Frank Rimerman Advisors LLC and MUFG Securities EMEA plc, have either increased their holdings or established new stakes in Humana, indicating significant institutional interest in the company.
• Humana recently reported quarterly earnings of $6.27 EPS, which missed analysts' consensus estimate, but revenue of $32.39 billion exceeded expectations, showing a 9.6% year-over-year growth.

Mizuho Securities USA LLC lessened its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 15.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,660 shares of the insurance provider's stock after selling 1,752 shares during the period. Mizuho Securities USA LLC's holdings in Humana were worth $2,556,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HUM. Revolve Wealth Partners LLC bought a new position in shares of Humana in the 4th quarter valued at $202,000. Raymond James Financial Inc. acquired a new stake in shares of Humana during the 4th quarter valued at $26,720,000. Bessemer Group Inc. boosted its holdings in shares of Humana by 2.0% during the 4th quarter. Bessemer Group Inc. now owns 6,518 shares of the insurance provider's stock valued at $1,655,000 after acquiring an additional 125 shares in the last quarter. Scotia Capital Inc. boosted its holdings in shares of Humana by 44.2% during the 4th quarter. Scotia Capital Inc. now owns 953 shares of the insurance provider's stock valued at $242,000 after acquiring an additional 292 shares in the last quarter. Finally, Sanders Capital LLC lifted its holdings in Humana by 2.3% during the 4th quarter. Sanders Capital LLC now owns 1,194,708 shares of the insurance provider's stock worth $303,109,000 after buying an additional 26,367 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Price Performance

Humana stock traded up $7.95 during mid-day trading on Friday, hitting $289.29. The stock had a trading volume of 726,249 shares, compared to its average volume of 1,730,030. The firm has a market capitalization of $34.79 billion, a P/E ratio of 22.20, a P/E/G ratio of 1.66 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm's 50 day moving average is $241.58 and its 200 day moving average is $253.94. Humana Inc. has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the company posted $6.96 EPS. The company's quarterly revenue was up 9.6% on a year-over-year basis. On average, sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HUM. Piper Sandler cut their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a report on Thursday, July 31st. Oppenheimer lifted their price objective on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Truist Financial decreased their target price on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Robert W. Baird decreased their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Finally, Wall Street Zen downgraded Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Eighteen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $281.45.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.